Tamarind trypsin inhibitor in chitosan–Whey protein nanoparticles reduces fasting blood glucose levels without compromising Insulinemia: a preclinical study
Autor(a) principal: | |
---|---|
Data de Publicação: | 2019 |
Outros Autores: | , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFRN |
Texto Completo: | https://repositorio.ufrn.br/handle/123456789/54725 |
Resumo: | In vivo studies show the benefits of the trypsin inhibitor isolated from tamarind (Tamarindusindica L.) (TTI) seeds in satiety and obesity. In the present study, TTI nanoencapsulation (ECW) was performed to potentialize the effect of TTI and allow a controlled release in the stomach. The impact on glycemia, insulin, and lipid profile was evaluated in Wistar rats overfed with a high glycemic index diet (HGLI). Characterization of the nanoparticles and in vitro stability in simulated gastrointestinal conditions, monitored by antitrypsin activity and HPLC, was performed. ECW and empty nanoparticles (CW) were administered by gavage, using 12.5 and 10.0 mg/kg, respectively. Both nanoformulations presented a spherical shape and smooth surface, with an average diameter of 117.4 nm (24.1) for ECW and 123.9 nm (11.3) for CW. ECW maintained the antitrypsin activity (95.5%) in the gastric phase, while TTI was completely hydrolyzed. In Wistar rats, the nanoformulations significantly reduced glycemia and HOMA IR, and ECW increased HDL-c compared to CW (p < 0.05).Pancreas histopathology of animals treated with ECW suggested an onset of tissue repair. Thenanoencapsulation provided TTI protection, gradual release in the desired condition, and improvement of biochemical parameters related to carbohydrate metabolism disorders,without compromising insulinemia |
id |
UFRN_b7499b6e050e345ed7f4df12003e5eca |
---|---|
oai_identifier_str |
oai:https://repositorio.ufrn.br:123456789/54725 |
network_acronym_str |
UFRN |
network_name_str |
Repositório Institucional da UFRN |
repository_id_str |
|
spelling |
Morais, Ana Heloneida de AraújoMatias, Lidia Leonize RodriguesCosta, Rafael Oliveira de AraújoPassos, Thais SouzaQueiroz, Jaluza Luana Cravalho deSerquiz, Alexandre CoelhoMaciel, Bruna Leal LimaSantos, Pedro Paulo de AndradeCamillo, Cristina da SilvaGonçalves, CatarinaAmado, Izabel RodriguezPastrana, Lorenzohttps://orcid.org/0000-0002-6460-911X2023-09-06T19:57:20Z2023-09-06T19:57:20Z2019MATIAS, Lídia L. R. et al. Tamarind trypsin inhibitor in chitosan–whey protein nanoparticles reduces fasting blood glucose levels without compromising insulinemia: a preclinical study. Nutrients, v. 11, n. 11, p. 2770, 2019.Disponível em: https://www.mdpi.com/2072-6643/11/11/2770. Acesso em: 7 jul. 2023.https://repositorio.ufrn.br/handle/123456789/5472510.3390/nu11112770NutrientsTamarindusindica L.encapsulationoverfeedingdigestionfasting glucoseinsulinTamarind trypsin inhibitor in chitosan–Whey protein nanoparticles reduces fasting blood glucose levels without compromising Insulinemia: a preclinical studyinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleIn vivo studies show the benefits of the trypsin inhibitor isolated from tamarind (Tamarindusindica L.) (TTI) seeds in satiety and obesity. In the present study, TTI nanoencapsulation (ECW) was performed to potentialize the effect of TTI and allow a controlled release in the stomach. The impact on glycemia, insulin, and lipid profile was evaluated in Wistar rats overfed with a high glycemic index diet (HGLI). Characterization of the nanoparticles and in vitro stability in simulated gastrointestinal conditions, monitored by antitrypsin activity and HPLC, was performed. ECW and empty nanoparticles (CW) were administered by gavage, using 12.5 and 10.0 mg/kg, respectively. Both nanoformulations presented a spherical shape and smooth surface, with an average diameter of 117.4 nm (24.1) for ECW and 123.9 nm (11.3) for CW. ECW maintained the antitrypsin activity (95.5%) in the gastric phase, while TTI was completely hydrolyzed. In Wistar rats, the nanoformulations significantly reduced glycemia and HOMA IR, and ECW increased HDL-c compared to CW (p < 0.05).Pancreas histopathology of animals treated with ECW suggested an onset of tissue repair. Thenanoencapsulation provided TTI protection, gradual release in the desired condition, and improvement of biochemical parameters related to carbohydrate metabolism disorders,without compromising insulinemiaengreponame:Repositório Institucional da UFRNinstname:Universidade Federal do Rio Grande do Norte (UFRN)instacron:UFRNinfo:eu-repo/semantics/openAccessORIGINALTamarindTrypsin_Matias_2019.pdfTamarindTrypsin_Matias_2019.pdfapplication/pdf6327752https://repositorio.ufrn.br/bitstream/123456789/54725/1/TamarindTrypsin_Matias_2019.pdfffd8a7bab377ffc1d3641e4f9d6701d2MD51LICENSElicense.txtlicense.txttext/plain; charset=utf-81484https://repositorio.ufrn.br/bitstream/123456789/54725/2/license.txte9597aa2854d128fd968be5edc8a28d9MD52123456789/547252023-09-06 16:57:20.717oai:https://repositorio.ufrn.br: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Repositório de PublicaçõesPUBhttp://repositorio.ufrn.br/oai/opendoar:2023-09-06T19:57:20Repositório Institucional da UFRN - Universidade Federal do Rio Grande do Norte (UFRN)false |
dc.title.pt_BR.fl_str_mv |
Tamarind trypsin inhibitor in chitosan–Whey protein nanoparticles reduces fasting blood glucose levels without compromising Insulinemia: a preclinical study |
title |
Tamarind trypsin inhibitor in chitosan–Whey protein nanoparticles reduces fasting blood glucose levels without compromising Insulinemia: a preclinical study |
spellingShingle |
Tamarind trypsin inhibitor in chitosan–Whey protein nanoparticles reduces fasting blood glucose levels without compromising Insulinemia: a preclinical study Morais, Ana Heloneida de Araújo Tamarindusindica L. encapsulation overfeeding digestion fasting glucose insulin |
title_short |
Tamarind trypsin inhibitor in chitosan–Whey protein nanoparticles reduces fasting blood glucose levels without compromising Insulinemia: a preclinical study |
title_full |
Tamarind trypsin inhibitor in chitosan–Whey protein nanoparticles reduces fasting blood glucose levels without compromising Insulinemia: a preclinical study |
title_fullStr |
Tamarind trypsin inhibitor in chitosan–Whey protein nanoparticles reduces fasting blood glucose levels without compromising Insulinemia: a preclinical study |
title_full_unstemmed |
Tamarind trypsin inhibitor in chitosan–Whey protein nanoparticles reduces fasting blood glucose levels without compromising Insulinemia: a preclinical study |
title_sort |
Tamarind trypsin inhibitor in chitosan–Whey protein nanoparticles reduces fasting blood glucose levels without compromising Insulinemia: a preclinical study |
author |
Morais, Ana Heloneida de Araújo |
author_facet |
Morais, Ana Heloneida de Araújo Matias, Lidia Leonize Rodrigues Costa, Rafael Oliveira de Araújo Passos, Thais Souza Queiroz, Jaluza Luana Cravalho de Serquiz, Alexandre Coelho Maciel, Bruna Leal Lima Santos, Pedro Paulo de Andrade Camillo, Cristina da Silva Gonçalves, Catarina Amado, Izabel Rodriguez Pastrana, Lorenzo |
author_role |
author |
author2 |
Matias, Lidia Leonize Rodrigues Costa, Rafael Oliveira de Araújo Passos, Thais Souza Queiroz, Jaluza Luana Cravalho de Serquiz, Alexandre Coelho Maciel, Bruna Leal Lima Santos, Pedro Paulo de Andrade Camillo, Cristina da Silva Gonçalves, Catarina Amado, Izabel Rodriguez Pastrana, Lorenzo |
author2_role |
author author author author author author author author author author author |
dc.contributor.authorID.pt_BR.fl_str_mv |
https://orcid.org/0000-0002-6460-911X |
dc.contributor.author.fl_str_mv |
Morais, Ana Heloneida de Araújo Matias, Lidia Leonize Rodrigues Costa, Rafael Oliveira de Araújo Passos, Thais Souza Queiroz, Jaluza Luana Cravalho de Serquiz, Alexandre Coelho Maciel, Bruna Leal Lima Santos, Pedro Paulo de Andrade Camillo, Cristina da Silva Gonçalves, Catarina Amado, Izabel Rodriguez Pastrana, Lorenzo |
dc.subject.por.fl_str_mv |
Tamarindusindica L. encapsulation overfeeding digestion fasting glucose insulin |
topic |
Tamarindusindica L. encapsulation overfeeding digestion fasting glucose insulin |
description |
In vivo studies show the benefits of the trypsin inhibitor isolated from tamarind (Tamarindusindica L.) (TTI) seeds in satiety and obesity. In the present study, TTI nanoencapsulation (ECW) was performed to potentialize the effect of TTI and allow a controlled release in the stomach. The impact on glycemia, insulin, and lipid profile was evaluated in Wistar rats overfed with a high glycemic index diet (HGLI). Characterization of the nanoparticles and in vitro stability in simulated gastrointestinal conditions, monitored by antitrypsin activity and HPLC, was performed. ECW and empty nanoparticles (CW) were administered by gavage, using 12.5 and 10.0 mg/kg, respectively. Both nanoformulations presented a spherical shape and smooth surface, with an average diameter of 117.4 nm (24.1) for ECW and 123.9 nm (11.3) for CW. ECW maintained the antitrypsin activity (95.5%) in the gastric phase, while TTI was completely hydrolyzed. In Wistar rats, the nanoformulations significantly reduced glycemia and HOMA IR, and ECW increased HDL-c compared to CW (p < 0.05).Pancreas histopathology of animals treated with ECW suggested an onset of tissue repair. Thenanoencapsulation provided TTI protection, gradual release in the desired condition, and improvement of biochemical parameters related to carbohydrate metabolism disorders,without compromising insulinemia |
publishDate |
2019 |
dc.date.issued.fl_str_mv |
2019 |
dc.date.accessioned.fl_str_mv |
2023-09-06T19:57:20Z |
dc.date.available.fl_str_mv |
2023-09-06T19:57:20Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
MATIAS, Lídia L. R. et al. Tamarind trypsin inhibitor in chitosan–whey protein nanoparticles reduces fasting blood glucose levels without compromising insulinemia: a preclinical study. Nutrients, v. 11, n. 11, p. 2770, 2019.Disponível em: https://www.mdpi.com/2072-6643/11/11/2770. Acesso em: 7 jul. 2023. |
dc.identifier.uri.fl_str_mv |
https://repositorio.ufrn.br/handle/123456789/54725 |
dc.identifier.doi.none.fl_str_mv |
10.3390/nu11112770 |
identifier_str_mv |
MATIAS, Lídia L. R. et al. Tamarind trypsin inhibitor in chitosan–whey protein nanoparticles reduces fasting blood glucose levels without compromising insulinemia: a preclinical study. Nutrients, v. 11, n. 11, p. 2770, 2019.Disponível em: https://www.mdpi.com/2072-6643/11/11/2770. Acesso em: 7 jul. 2023. 10.3390/nu11112770 |
url |
https://repositorio.ufrn.br/handle/123456789/54725 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.publisher.none.fl_str_mv |
Nutrients |
publisher.none.fl_str_mv |
Nutrients |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFRN instname:Universidade Federal do Rio Grande do Norte (UFRN) instacron:UFRN |
instname_str |
Universidade Federal do Rio Grande do Norte (UFRN) |
instacron_str |
UFRN |
institution |
UFRN |
reponame_str |
Repositório Institucional da UFRN |
collection |
Repositório Institucional da UFRN |
bitstream.url.fl_str_mv |
https://repositorio.ufrn.br/bitstream/123456789/54725/1/TamarindTrypsin_Matias_2019.pdf https://repositorio.ufrn.br/bitstream/123456789/54725/2/license.txt |
bitstream.checksum.fl_str_mv |
ffd8a7bab377ffc1d3641e4f9d6701d2 e9597aa2854d128fd968be5edc8a28d9 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFRN - Universidade Federal do Rio Grande do Norte (UFRN) |
repository.mail.fl_str_mv |
|
_version_ |
1814833003349671936 |